Aug 8, 2007 by Brian LawlerExelixis Feeling LovedExelixis reveals what's up ahead for the rest of 2007.
Aug 7, 2007 by Brian LawlerEncysive's Congested Sales FailureEncysive announces its plans for its lead drug.
Aug 7, 2007 by Brian LawlerKing Holds Onto Its CrownKing announces its second-quarter financial results.
Aug 6, 2007 by Brian LawlerInterMune's On TrackInterMune reiterates its goals for this year and next.
Aug 6, 2007 by Brian LawlerUnhappy Delays for MannKindTwo delays for MannKind cause the stock to drop.
Aug 6, 2007 by Brian LawlerDon't Discount ViroPharmaViroPharma announces its second-quarter financial results.
Aug 3, 2007 by Brian LawlerCephalon's Case of Spending BluesCephalon announces its second-quarter financial results.
Aug 3, 2007 by Brian LawlerVanda Announces Some Late-Stage ManeuversVanda gets ready for a busy remainder of 2007.
Aug 3, 2007 by Brian LawlerEndo Adjusting to Bigger HopesEndo announces its second-quarter financial results.
Aug 2, 2007 by Brian LawlerUnited Therapeutics Unites R and DThe drugmaker quietly beats the market while vying for its share of customers.
Aug 2, 2007 by Brian LawlerPDL Minds Its Mild MannersThe drugmaker announces placid second-quarter results.
Aug 2, 2007 by Brian LawlerHuman Genome AdvancesHuman Genome Sciences updates investors on what to expect.
Aug 1, 2007 by Brian LawlerCV Therapeutics' Turnaround QuarterCV Therapeutics provides its second-quarter financial results.
Aug 1, 2007 by Brian LawlerWatch These Four Drug DevelopersA look at four drugmakers that deserve to be on any investor's watch list.
Aug 1, 2007 by Brian LawlerA Closer Look at VandaTaking a closer look at whether Vanda's lead drug will get FDA approval.
Aug 1, 2007 by Brian LawlerNeurocrine Awaits Its DestinyNeurocrine updates investors on its plans for the rest of the year.
